Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Blood (2023) 142 (Supplement 1): 446.

https://doi.org/10.1182/blood-2023-182792

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Thomas Ernst, Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 807–808.

https://doi.org/10.1182/blood-2022-165041

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Philipp le Coutre, Joachim R Göthert, Susanne Saussele, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Andreas Burchert

Blood (2022) 140 (Supplement 1): 12202–12203.

https://doi.org/10.1182/blood-2022-162281

Published: 2022

Journal Articles

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Körber, Kim Kricheldorf, Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Griesshammer, Konstanze Döhner, Steffen Koschmieder

Blood (2022) 140 (Supplement 1): 6874–6876.

https://doi.org/10.1182/blood-2022-165034

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus

Blood (2021) 138 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2021-150352

Published: 2021

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Blood (2018) 132 (Supplement 1): 460.

https://doi.org/10.1182/blood-2018-99-112119

Published: 2018

Journal Articles

Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients

Annamaria Brioli, MD, vom Hofe Felix, Lars-Olof Mügge, MD, Sebastian Scholl, MD, Inken Hilgendorf, MD, Herbert G. Sayer, MD PhD, Olaposi Yomade, MD, Thomas Ernst, Andreas Hochhaus, MD, Marie von Lilienfeld-Toal, MD

Blood (2018) 132 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2018-99-112045

Published: 2018

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

Georg Hess, Andreas Hüttmann, MD, Julia Meissner, MD, Reinhard Marks, Martin Dreyling, MD PhD, Ulrich Keller, Thomas Ernst, Christiane Pott, Andreas Viardot, MD, Oliver Deuster, Christina van Oordt, Matthias Theobald, Georg Lenz

Blood (2018) 132 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2018-99-116670

Published: 2018

Journal Articles

DNA Analysis of Mutations in the Kinase Domain of BCR-ABL1 By Allele-Specific Digital PCR Is Highly Sensitive and Refines Prediction of Kinetics of Resistant CML Clones

Vaclava Polivkova, Nikola Curik, Hana Zizkova, Adela Benesova, Pavel Burda, Pavla Pecherkova, Eliska Motlova, Jana Brezinova, Sarka Ransdorfova, Hana Klamova, Lenka Hovorkova, Jan Zuna, Thomas Ernst, Simona Soverini, PhD, Katerina Machova

Blood (2018) 132 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2018-99-119710

Published: 2018

Journal Articles

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response

Blood (2018) 132 (3): 307–320.

https://doi.org/10.1182/blood-2017-10-810986

Published: 2018

Includes: Supplemental data

Journal Articles

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Christine Günther, Michael Cross, PhD, Thomas Ernst, MD, Christian Fabisch, PhD, Dietger Niederwieser, MD, Andreas Hochhaus, MD, Thoralf Lange, MD

Blood (2017) 130 (Supplement 1): 252.

https://doi.org/10.1182/blood.V130.Suppl_1.252.252

Published: 2017

Journal Articles

Prevalence and Dynamics of Clonal Hematopoiesis Caused By Leukemia Associated Mutations in Elderly Individuals without Hematologic Disorders

Thomas Ernst, MD, Jenny Rinke, Danica Midic, Violetta Müller, Anja Waldau, Alexander Kaiser, MD, Bernd Gruhn, Jürgen Landschulze, MD, Frank Pester, MD, Andreas Hochhaus, MD

Blood (2017) 130 (Supplement 1): 1141.

https://doi.org/10.1182/blood.V130.Suppl_1.1141.1141

Published: 2017

Journal Articles

Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Patients with Chronic Myeloid Leukemia

Thomas Ernst, MD, Jenny Rinke, Melinda Busch, Jana Ernst, MD, Ellen Obstfelder, Mathias Schmidt, MD, Vivien Schäfer, Anja Waldau, Nils Winkelmann, MD, Bernd Gruhn, MD, Andreas Hochhaus, MD

Blood (2016) 128 (22): 1221.

https://doi.org/10.1182/blood.V128.22.1221.1221

Published: 2016

Journal Articles

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Sebastian Birndt, Thomas Schenk, MD, Frank M. Brunkhorst, MD, Georg Maschmeyer, MD, Frank Rothmann, MD, Thomas Weber, MD, Markus Müller, MD, Jens P. Panse, MD, Roland Schroers, MD, Jan Braess, MD, Norbert Frickhofen, MD, Gritta Janka, MD PhD, Kai Lehmberg, MD, Andreas Hochhaus, MD, Thomas Ernst, MD, Paul La Rosée, MD

Blood (2016) 128 (22): 2523.

https://doi.org/10.1182/blood.V128.22.2523.2523

Published: 2016

Journal Articles

Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration

Thomas Ernst, MD, Vivien Schäfer, Helen E White, PhD, Susanne Saussele, MD, Thoralf Lange, MD, Gareth Gerrard, PhD, Nicholas CP Cross, PhD, Andreas Hochhaus, MD

Blood (2016) 128 (22): 1918.

https://doi.org/10.1182/blood.V128.22.1918.1918

Published: 2016

Journal Articles

Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia

Lai N Chan, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Gang Xiao, PhD, Zhengshan Chen, MD PhD, Thomas Ernst, MD, Andreas Hochhaus, MD, Markus Müschen, MD PhD

Blood (2016) 128 (22): 2771.

https://doi.org/10.1182/blood.V128.22.2771.2771

Published: 2016

NARROW

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

DNA Analysis of Mutations in the Kinase Domain of BCR-ABL1 By Allele-Specific Digital PCR Is Highly Sensitive and Refines Prediction of Kinetics of Resistant CML Clones

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Prevalence and Dynamics of Clonal Hematopoiesis Caused By Leukemia Associated Mutations in Elderly Individuals without Hematologic Disorders

Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Patients with Chronic Myeloid Leukemia

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration

Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only